SEC Form 4 research
| Issuer | LIGAND PHARMACEUTICALS INC |
|---|---|
| Tickers | LGND, LGNDD |
| Reporting owners | 56 |
| Officers and directors | 22 |
| Last public filing | 2026-11-06 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-11-06 | 2026-11-04 | Aryeh Jason | S | 282 | $319.99 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 80 | $314.58 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 403 | $313.75 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 634 | $312.85 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 520 | $311.72 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 490 | $310.61 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 522 | $309.91 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 708 | $308.43 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 283 | $307.39 | Not reported |
| 2026-11-04 | 2026-11-02 | Reardon Andrew | S | 120 | $323.14 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.